ClinicalTrials.gg

Program

BMB-101

A development code.

Its studies are mostly in Prader-Willi Syndrome · Epilepsy, Absence, led by Bright Minds Biosciences Pty.

Furthest: phase 2, since May 2, 20243 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bright Minds Biosciences Pty32 open or runningphase 2since May 2, 2024May 19, 2022Nov 2026phase 2 · NCT07266324

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2022First study: phase 1 study in HealthyFirst studyNCT05397041 · 81 enrolled · Australia
  2. May 2, 2024Phase 2 study in Epilepsy, AbsenceNCT06401538 · 20 planned · Australia
  3. Nov 17, 2025Phase 2 study in Prader-Willi SyndromeNCT07266324 · 16 planned · Australia

Ahead

  1. Nov 2026Primary completion: phase 2 study in Prader-Willi SyndromeNCT07266324

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07266324Prader-Willi Syndrome · Australia2Not yet recruitingNov 202616
NCT06401538Epilepsy, Absence · Australia2RecruitingSep 15, 202520
NCT05397041Healthy · Australia1CompletedMay 4, 202381

How it is read

Names in the registry

  • “BMB-101”, 3 entries

Codes read as this program: BMB101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.